Overview

• Johnston v. LifeMD, Inc. has been filed in the Eastern District of New York, covering investors who bought shares between May 7 and August 5, 2025.
• Plaintiffs allege the company raised full‑year revenue and adjusted EBITDA guidance on May 6, 2025 without disclosing rising acquisition costs at RexMD and elevated refund rates in weight‑management offerings.
• The complaint cites company statements promoting a “category‑defining competitive moat” in virtual obesity care and strong RexMD performance as misleading.
• LifeMD reported a second‑quarter miss on August 5, 2025 and cut guidance citing temporary higher acquisition costs and refund issues, after which the stock fell about 44% the next trading day.
• Hagens Berman, Pomerantz, and Levi & Korsinsky are soliciting shareholders, with notices listing differing lead‑plaintiff deadlines of October 27 and October 25, and one firm inviting whistleblower tips under the SEC program.